Mario Vukic, MD
Neurology · Hackensack, NJNPI 1043287865
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $238,089 of the $309,865 with a category attached, or 76.8%. 24 manufacturers reported payments, led by Argenx US, Inc. at 47.1% of the total. 2025 is the largest year on record at $149,352, more than ten times the $14 reported in 2019. Among neurology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 626 payments — averaging $494.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Argenx US, Inc.$146K
- UCB, Inc.$76K
- AstraZeneca$47K
- Amgen$21K
- Johnson & Johnson$18K
- Teva Pharmaceuticals USA, Inc.$402
- plus $2K from 18 others
What the payments were for
- Consulting fees$12,5854%
- Speaking & faculty fees$238,08977%
- Travel & lodging$45,99615%
- Food & beverage$13,1964%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Argenx US, Inc. | 213 | $145,920 |
| UCB, Inc. | 120 | $76,148 |
| AstraZeneca | 84 | $46,653 |
| Amgen | 31 | $21,177 |
| Johnson & Johnson(2 entities) | 34 | $17,959 |
| Teva Pharmaceuticals USA, Inc. | 48 | $402 |
| AbbVie | 28 | $273 |
| Novartis | 12 | $229 |
| Pfizer | 12 | $219 |
| TG Therapeutics, Inc. | 8 | $151 |
| Janssen Scientific Affairs, LLC | 1 | $149 |
| EMD Serono, Inc. | 9 | $128 |
| Bristol Myers Squibb | 5 | $81 |
| Grifols USA, LLC | 3 | $61 |
| CSL Behring | 3 | $60 |
| SK Life Science, Inc. | 3 | $53 |
| Lundbeck LLC | 3 | $50 |
| Biogen | 2 | $36 |
| Alnylam Pharmaceuticals Inc. | 2 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $18 |
| Impel Pharmaceuticals Inc. | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$309,865 in reported general payments places this provider in the 95th percentile of 521 neurology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Vyvgart HytruloEfgartigimod-Hyaluronidas-Qvfc | 45 | $2,584,337 |
| VyvgartEfgartigimod Alfa-Fcab | 44 | $2,530,816 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 155 | $1,911,935 |
| UltomirisRavulizumab-Cwvz | 30 | $1,653,600 |
| ZilbrysqZilucoplan Sodium | 24 | $858,196 |
| SolirisEculizumab | 14 | $722,659 |
| Kesimpta PenOfatumumab | 15 | $125,400 |
| CopaxoneGlatiramer Acetate | 12 | $82,261 |
| Pyridostigmine Bromide | 101 | $14,099 |
| Memantine Hcl | 334 | $12,595 |
| Gabapentin | 304 | $6,672 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 143 | $5,562 |
| Dimethyl Fumarate | 24 | $3,680 |
| Mycophenolate Mofetil | 45 | $3,660 |
| RivastigmineRivastigmine Tartrate | 32 | $2,596 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Argenx US, Inc.Vyvgart Hytrulo, Vyvgart | $145,920 | $5,115,15489 claims |
| AstraZenecaUltomiris, Soliris | $46,653 | $2,376,25944 claims |
| Grifols USA, LLCGamunex-C | $61 | $1,911,935155 claims |
| UCB, Inc.Zilbrysq | $76,148 | $858,19624 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $402 | $82,26112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 521 neurology providers in New Jersey.
Other neurology in Hackensack
- Regina KrelHackensack$182K
- Steven BromleyAudubon$1.5M
- Mary Ann PiconeTeaneck$1.5M
- Fiona GuptaOradell$1.1M
- Matthew DavisMiddletown$567K
- Amos KatzEatontown$558K
- Monte PellmarFreehold$429K
- Marcie RabinSummit$387K
- Ashish KapoorBayonne$329K
- Andrew SylvesterBridgewater$296K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.